Methyl 2-hydroxy-3,3-diphenyl-3-(2-phenylethoxy)propanoate | 1025914-18-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: Methyl 2-hydroxy-3,3-diphenyl-3-(2-phenylethoxy)propanoate
• CAS: 1025914-18-4
• 化学式: C₂₄H₂₄O₄
• 分子量: 376.452
• InChiKey: BAHNQAZETPPDBY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.3
• 重原子数：
  28
• 可旋转键数：
  9
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.21
• 拓扑面积：
  55.8
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  Methyl 2-hydroxy-3,3-diphenyl-3-(2-phenylethoxy)propanoate 在 sodium hydroxide 、 lithium amide 作用下， 以 1,4-二氧六环 、 N,N-二甲基甲酰胺 为溶剂， 反应 20.0h， 生成 3-(2-phenylethoxy)-2-<(4,6-dimethylpyrimidin-2-yl)oxy>-3,3-diphenylpropionic acid
  参考文献：
  名称：

  Discovery and Synthesis of (S)-3-[2-(3,4-Dimethoxyphenyl)ethoxy]-2- (4,6-dimethylpyrimidin-2-yloxy)-3,3-diphenylpropionic Acid (LU 302872), a Novel Orally Active Mixed ET_A/ET_B Receptor Antagonist

  摘要：

  Structural variation of the endothelin A-selective antagonist (S)-3-methoxy-2-(4,6-dimethoxy-pyrimidin-2-yloxy)-3,3-diphenylpropionic acid (LU 135252) led to analogues which retain ETA affinity but exhibit substantial ETB affinity as well. The most active derivative obtained is (S)-3- [2-(3,4-dimethoxyphenyl)ethoxy]-2-(4,6-dimethylpyrimidin-2-yloxy)-3,3-diphenylpropionic acid (LU 302872), which can be prepared in enantiomerically pure form in eight steps via an acid-catalyzed transetherification. It has a K-i = 2.15 nM far binding to the ETA receptor and a K-i = 4.75 nM for binding to the ETB receptor, is orally available, and antagonizes the big ET-induced blood pressure increase in rats and the big ET-induced bronchospasm in guinea pigs each time at a dose of 10 mg/kg.

  DOI：

  10.1021/jm9910425
• 作为产物：
  描述：

  苯乙醇 、 3, 3-二苯基-2,3-环氧丙酸甲酯 在 三氟化硼乙醚 作用下， 以 二氯甲烷 为溶剂， 反应 2.0h， 生成 Methyl 2-hydroxy-3,3-diphenyl-3-(2-phenylethoxy)propanoate
  参考文献：
  名称：

  Discovery and Synthesis of (S)-3-[2-(3,4-Dimethoxyphenyl)ethoxy]-2- (4,6-dimethylpyrimidin-2-yloxy)-3,3-diphenylpropionic Acid (LU 302872), a Novel Orally Active Mixed ET_A/ET_B Receptor Antagonist

  摘要：

  Structural variation of the endothelin A-selective antagonist (S)-3-methoxy-2-(4,6-dimethoxy-pyrimidin-2-yloxy)-3,3-diphenylpropionic acid (LU 135252) led to analogues which retain ETA affinity but exhibit substantial ETB affinity as well. The most active derivative obtained is (S)-3- [2-(3,4-dimethoxyphenyl)ethoxy]-2-(4,6-dimethylpyrimidin-2-yloxy)-3,3-diphenylpropionic acid (LU 302872), which can be prepared in enantiomerically pure form in eight steps via an acid-catalyzed transetherification. It has a K-i = 2.15 nM far binding to the ETA receptor and a K-i = 4.75 nM for binding to the ETB receptor, is orally available, and antagonizes the big ET-induced blood pressure increase in rats and the big ET-induced bronchospasm in guinea pigs each time at a dose of 10 mg/kg.

  DOI：

  10.1021/jm9910425